The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

PD-L1 expression and progression risk of stage III NSCLC patients on durvalumab consolidation.

Khalid  Jazieh

No Relationships to Disclose

Mohamed  Gad

No Relationships to Disclose

Anas M  Saad

No Relationships to Disclose

Nathan A.  Pennell

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Cota Healthcare; Genentech; Inivata; Lilly; Merck; Regeneron

Research Funding - Altor BioScience (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Jounce Therapeutics (Inst); Loxo (Inst); Merck (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)